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THE USE OF TANDEM MASS SPECTROMETRY IN 
NEWBORN SCREENING: AUSTRALIA’S EXPERIENCE 
AND ITS IMPLICATIONS FOR UNITED STATES POLICY 
Lauren E. Fisher† 
Abstract:  In recent years, the United States has drastically increased the number of 
disorders screened through its newborn screening programs.  This increase is made 
possible by the adoption of new a technology, the tandem mass spectrometer (“MS/MS”), 
which allows screening of up to thirty disorders from a single drop of a newborn’s blood.  
However, such rapid expansion of screening raises concerns regarding the purpose of the 
screening, as well as the current practices in place for obtaining informed consent.  
Similar expansion in Australia provides a model of one approach to address these 
difficult questions.  As the first country to begin using MS/MS for newborn screening, 
the Australian experience sheds light on the implications surrounding such expansion, as 
well as one method for resolving these issues.  However, close analysis reveals that the 
Australian method for expanding screening would cause dissonance within the U.S. legal 
system, specifically with regard to informed consent.  Therefore, the American states 
need to re-evaluate the implications of this screening in order to assess whether or not 
such vast expansion is a good idea.  Policy-makers must use caution prior to 
incorporating any new disorders into newborn screening in order to protect the rights of 
one of the most vulnerable citizens in our society – the newborn baby. 
I. INTRODUCTION 
Newborn screening is the most common type of genetic testing 
practiced in the United States today.1  These programs are responsible for 
collection of blood samples, screening, and follow-up for approximately four 
million births each year.2  In the U.S., newborn screening is both run and 
financed by the states.3  State policy-makers also determine when to screen 
                                           
†
  The author would like to thank Professor Anna Mastroianni for her guidance and assistance in 
writing this comment.  I truly appreciate your comments.  I would also like to thank Professor Kate 
Batuello for her assistance with research.  My editors, Rebecca Jacobs, Katherine Van Maren and Alyssa 
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1
   NORTH CAROLINA CENTER FOR GENOMICS AND PUBLIC HEALTH, GENETIC TESTING, available at 
http://www.sph.unc.edu/nccgph/phgenetics/testing.htm (last visited Oct. 30, 2005). 
2
   See Leah Oliver, Newborn Genetic Screening, Genetics Brief Issue No. X: National Conference of 
State Legislatures (2002); U.S. Department of Health and Human Services, 1998 National Newborn 
Screening Report 16 (2001) [hereinafter National NBS Report]. 
3
  See Linda L. McCabe et al., Newborn Screening: Rationale for a Comprehensive Fully Integrated 
Public Health System, 77 MOLECULAR GENETICS & METABOLISM 267, 269 (2002). 
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newborns, as well as the types of disorders to include within their screening 
panel.4  
One of the more difficult tasks facing states is deciding which 
disorders to incorporate in the screening panel.  A number of governmental 
and nongovernmental advisory committees developed lists of criteria to 
allow states to make these decisions in a deliberate and uniform fashion.5  
However, the degree to which the states rely upon these criteria differs, 
creating disparity in the number and type of disorders screened among the 
various states.6  As a result, “which side of a state border an infant is born on 
can make a life-or-death difference.”7 
New technology now allows states to screen for more disorders from a 
single drop of blood.8  More than forty states are already utilizing this new 
technology – the tandem mass spectrometer (“MS/MS”).9  The number of 
disorders included within many states’ screening panels has significantly 
increased due to the adoption of MS/MS.10  This increase has led to criticism 
surrounding the inadequacies of MS/MS,11 focusing on the lack of controlled 
studies regarding treatment, as well as a lack of accurate diagnoses for the 
disorders now included in screening.12  The question currently facing policy-
                                           
4
   The term “screening panel” refers to the panel of disorders screened for in any particular state.  
Including a disorder within the screening panel places a duty upon the state to have the necessary follow-up 
care in place in the event that a child receives a positive test result.  See id. 
5
   See McCabe et al., supra note 3, at 269. 
6
  According to the National Newborn Screening and Genetics Resource Center, states currently 
screen for anywhere from 4 to more than 30 disorders.  See National Newborn Screening and Genetics 
Resource Center, U.S. NATIONAL SCREENING REPORT (last updated Sept. 22, 2005), available at 
http://genes-r-us.uthscsa.edu/nbsdisorders.pdf (last visited Oct. 1, 2005) [hereinafter U.S. NATIONAL 
SCREENING REPORT]. 
7
  Susan Brink, Rare But Deadly, U.S. NEWS & WORLD REP., May 30, 2005, available at 
www.usnews.com/usnews/health/articles/050530/30child.htm (last visited Oct. 1, 2005). 
8
  See McCabe et al., supra note 3, at 270. 
9
  See U.S. National Screening Report, supra note 6. 
10
  In 1998, the National NBS and Genetics Resource Center reported that the range of disorders 
included in state newborn screening programs was 4 to 8.  Their most recent report indicates that some 
states are now testing for well over 30 disorders, primarily through MS/MS.  See id.  
11
  See Susan E. Waisbren et al., Effect of Expanded Newborn Screening for Biochemical Genetic 
Disorders on Child Oucomes and Parental Stress, 290 JAMA  2564, 2565 (2003) (the “expansion of 
mandatory screening … has proceeded despite concerns”). 
12
  See Bridget Wilcken et al., Screening Newborns for Inborn Errors of Metabolism by Tandem 
Mass Spectrometry, 348 NEW ENG. J. MED. 2304, 2304, 2311 (2003) (discussing how use of MS/MS for 
newborn screening results in identifying patients as having a disorder when if fact they have only a mild, or 
perhaps benign form that will never result in symptoms.  It is not currently possible to determine which of 
the patients were indeed at risk, and whether treatment decreases decompensation or death after diagnosis 
because “formal studies are lacking.”); see also M. J. Thomason et al., A Systematic Review of Evidence for 
the Appropriateness of Neonatal Screening Programmes for Inborn Errors of Metabolism, 20 J. PUB. 
HEALTH & MED. 331 (1998). 
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makers is what, if anything, should be done in response to the rapid increase 
of screening occurring throughout the United States. 
Australian newborn screening programs have used MS/MS since 
1998.13  Their experience has shown that the technology detects more 
newborns with genetic variances potentially connected to inborn errors of 
metabolism than were detected under previous screening methods.14  
However, the program also revealed that scientists do not know enough 
about many of these disorders to accurately predict whether a child with a 
positive result will actually suffer from that disorder.15  This lack of 
knowledge prevented some of the disorders from meeting the criteria used to 
determine which disorders to include in the Australian states’ screening 
panels.16  To address this issue, the Australian advisory committee 
responsible for setting these criteria17 altered some of the language of their 
policy recommendations to justify screening for these new disorders within 
the Australian states.18   
While a simple change in the language of the criteria for screening 
worked in Australia, a similar change in the United States would violate 
well-established legal principles, such as personal autonomy and informed 
consent.  Therefore, the American states should examine the rapid addition 
of disorders to their screening panels by looking at the results of the 
Australian report. 
This Comment argues that the United States should proceed with 
caution in expansion of its newborn screening programs.  Part II analyzes the 
history of screening in the United States, as well as the criteria traditionally 
relied upon by state legislators in determining which disorders to include in 
screening.  Part III briefly describes MS/MS, as well as the potential benefits 
it offers to newborn screening programs.  Part IV evaluates the Australian 
experience utilizing MS/MS, and the implications of the results of that 
                                           
13
  See Wilcken et al., supra  note 12, at 2305. 
14
  Id. 
15
  Id. 
16
  Human Genetics Society of Australia (“HGSA”) Policy Statement 1999, HGSA-Royal 
Australasian College of Physicians (“RACP”) Newborn Screening Joint Subcommittee; Newborn Blood-
Spot Screening (1999) (copy on file with the Journal) [hereinafter HGSA Policy Statement 1999]. 
17
  Within Australia, the HGSA and RACP form a joint subcommittee to draft policy statements on 
issues such as newborn screening.  The individual states rely upon these statements when drafting their 
policies.  The criteria developed by the HGSA-RACP for newborn screening assist states in determining 
which disorders to include in a screening panel.  HGSA Policy Statement for Developing New Policies 
(Sept. 2000), available at http://www.hgsa.com.au/ (last visited Oct. 1, 2005). 
18
  HGSA Policy Statement 2004, HGSA-RACP Newborn Screening Joint Subcommittee; Newborn 
Blood-Spot Screening (March 18, 2004), available at http://www.hgsa.com.au/Word/HGSApolicy 
StatementNewbornScreening0204-18.03.04.doc (last visited Oct. 1, 2005) [hereinafter HGSA Policy 
Statement 2004]. 
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program.  This section includes a discussion on medium-chain acyl-CoA 
dehydrogenase deficiency (“MCADD”), focusing on the over-detection of 
this disorder through MS/MS screening.  Part V suggests that because some 
of the disorders do not meet the criteria required to include them in a 
screening panel, states should progress with caution prior to the 
incorporation of more disorders into these panels.  This section also includes 
an evaluation of how Australia’s criteria changed to allow for the addition of 
these disorders.  This Comment concludes with a discussion on how 
informed consent may prohibit the states from making similar changes to 
their screening policies.  State policy-makers should examine this informed 
consent issue and re-evaluate their programs before deciding to expand the 
number of disorders screened.  Such analysis will lead them in the future to 
employ a more cautious approach prior to expanding screening.   
II. NEWBORN SCREENING WITHIN THE UNITED STATES MINIMIZES A 
NEWBORN’S RISK OF MULTIPLE DISORDERS  
Newborn screening programs within the United States have evolved to 
the point where they now successfully minimize a newborn’s risk of 
developing a number of inborn errors of metabolism.  All fifty states and the 
District of Columbia currently have legislation in place to standardize 
newborn screening.19  This legislation typically delegates authority to the 
state public health department, which oversees the implementation of the 
program.20  However, this type of screening has not always been available, 
and is in fact a fairly recent development in healthcare dating back only to 
the 1960s.21 
A. The United States’ Newborn Screening Programs Have Developed to 
Benefit the Newborn 
In response to the initial test developed to screen for phenylketonuria 
(“PKU”), the United States has implemented screening programs designed 
to benefit the health of all newborns.  In 1961, microbiologist Robert 
                                           
19
  See Bradford L. Therrell, Jr., U.S. Newborn Screening Policy Dilemmas for the Twenty-first 
Century, 74 MOLECULAR GENETICS AND METABOLISM, 64, 67 (2001). For a list of state legislation see 
Alissa Johnson, Newborn Genetic and Metabolic Disease Screening, NATIONAL COUNCIL OF STATE 
LEGISLATURES (2005), at http://www.ncsl.org/programs/health/genetics/newborn.htm (last visited Oct. 1, 
2005). 
20
  See Ellen Wright Clayton, Screening and Treatment of Newborns, 29 HOUS. L. REV. 85, 99 
(1992). 
21
  See U.S. GEN. ACCOUNTING OFFICE, REPORT TO CONGRESSIONAL REQUESTERS, Newborn 
Screening: Characteristics of State Programs, 4 (2003), available at http://www.gao.gov/new.items 
/d03449.pdf [hereinafter GAO Report] (last visited Oct. 1, 2005). 
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Guthrie22 invented an inexpensive and simple blood test to screen for the 
presence of PKU in newborns.23  PKU occurs when a child has a defect in an 
enzyme necessary to break down an amino acid present in most foods.24  
Without this enzyme, the amino acid collects within the child’s blood 
causing severe mental retardation.25  However, with proper treatment 
consisting of a special diet containing little to no phenylalanine, a child can 
avoid most, if not all, of the effects of this disease.26   
After watching the effects of PKU on his niece, Guthrie became 
determined to create a test usable for mass, population-based screening.27  
The result of his work was a simple test in which healthcare workers collect 
a small drop of the newborn’s blood on filter paper and then analyze it for 
the presence of a genetic marker indicating whether the child in question has 
PKU.28  Guthrie achieved his objective through this test and opened the door 
for mass screening of PKU in newborns.  He then began to promote the 
passage of state laws mandating PKU screening for all newborns.29  
Initially, the medical community resisted accepting PKU testing on 
newborns.30  Scientists estimate this disorder has an incidence in the United 
States, Britain, and most of Western Europe between one in 11,000 to 15,000 
births,31 and the rarity caused hesitation in mandating such wide-spread 
screening.32  However, Guthrie, along with the National Association for 
Retarded Citizens, exerted pressure upon the states and eventually succeeded 
in persuading Massachusetts to institute a large-scale pilot program utilizing 
                                           
22
  Robert Guthrie was a research scientist at Roswell Park Cancer Institute in Buffalo, New York, as 
well as a faculty member at the University of Buffalo School of Medicine and Biomedical Sciences at the 
time of this discovery.  He later became a professor emeritus of pediatrics and microbiology at the 
University of Buffalo.  Throughout his life, he was also a surgeon with the National Institute of Health and 
a professor and chair of the Department of Bacteriology and Immunology at the University of Kansas.  He 
retired in 1986 and died in 1995 in Seattle, Washington.  Obituaries: Robert Guthrie, Professor; Developer 
of PKU Test, U. BUFFALO REP., Aug. 31, 1995, available at http://www.buffalo.edu/reporter 
/vol27/vol27n01/n14.html (last visited Oct. 1, 2005). 
23
  See Robert Guthrie, Blood Screening for Phenylketonuria, 178 JAMA 863 (1961); Robert Guthrie 
& Ada Susi, A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of 
Newborn Infants, 32 PEDIATRICS 338 (1963). 
24
  See Diane B. Paul, The Politics of Heredity: Essays on Eugenics, Biomedicine, and the Nature-
Nurture Debate 173 (1998). 
25
  See Donal H. Chace & Theodore A. Kalas, A Biochemical Perspective on the Use of Tandem 
Mass Spectrometry for Newborn Screening and Clinical Testing, 38 CLINICAL BIOCHEMISTRY 296 (2005).  
26
  See PAUL, supra note 24. 
27
  See Therrell, supra note 19. 
28
  See GAO Report, supra note 21, at 14-15 (2003).  
29
 See Harvy L. Levy & Simone Albers, Genetic Screening of Newborns, 200.01 ANN. REV. 
GENOMICS HUM. GENETICS 139, 140 (2000); L.B. Andrews, State Laws and Regulations Governing 
Newborn Screening, 1985 CHICAGO: AM. BAR FOUND. 167 (1985). 
30
  See Therrell, supra note 19. 
31
  See PAUL, supra note 24. 
32
  Id. 
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the test on newborns.33  Finally, in 1963, Massachusetts adopted mandatory 
testing for PKU on all newborns.34  By the late 1960s, almost every state had 
mandated PKU testing on all newborns,35 and by 1975, Guthrie’s test was 
mandatory in 43 states,36 covering an estimated 90% of all newborns born in 
the United States.37 
The widespread acceptance of PKU testing in the United States was 
not an indication that the test was flawless.  In fact, much remained 
unknown about the disease, thus decreasing the reliability of the initial 
tests.38  Specifically, many questions remained regarding the disease’s 
diagnosis.39  In 1970, a survey indicated that the false-positive rate (those 
receiving a positive test result that did not actually have the disease) was 
abnormally high;40 for every infant identified who actually had the disease, 
an estimated nineteen others received false identification from the test.41  
More troubling was the fact that these false diagnoses were not harmless.42  
The severely restricted diet used to treat children with a PKU diagnosis 
ironically caused mental retardation, the condition it was designed to 
prevent, in some of the children who falsely tested positive.43  In 1975, the 
National Research Council Committee on Inborn Errors of Metabolism 
issued a statement in which they admitted that “screening was started, 
frequently under mandatory laws, when questions regarding diagnosis, 
prognosis, and optimal management were unanswered.”44  Eventually 
scientists learned enough about the disorder to reduce the false positive rate 
to an acceptable level.45  However, states could have avoided this problem 
had the test not been so rapidly adopted.46   
                                           
33
  See American Academy of Pediatrics, Serving the Family from Birth to the Medical Home, 106 
PEDIATRICS 389, 389-390 (2000)  [hereinafter AAP]; PAUL, supra note 24, at 174. 
34
  PAUL, supra note 24, at 173. 
35
  Levy & Albers, supra note 29, at 140. 
36
  See AAP, supra note 33. 
37
  NATIONAL RESEARCH COUNCIL COMMITTEE FOR THE STUDY OF INBORN ERRORS OF METABOLISM,  
GENETIC SCREENING: PROGRAMS, PRINCIPLES, AND RESEARCH, 23 (National Academy of Sciences: 
Washington, D.C. 1975). 
38
  Id. at 28. 
39
  See PAUL, supra note 24, at 177. 
40
  Id. 
41
  Id. 
42
  See Clayton, supra note 20, at 106; see also Gina Kolata, Panel to Advise Testing Babies for 29 
Diseases, N.Y. TIMES, February 21, 2005. 
43
  See Clayton, supra note 20, at 105; Kolata, supra note 42. 
44
  See Therrell, supra note 19, at 69-70 (citing National Research Council Committee for the Study 
of Inborn Errors of Metabolism, Genetic Screening: Programs, Principles, and Research 32 (1975)). 
45
  See Clayton, supra note 20, at 106. 
46
  See id.; Kolata, supra note 42. 
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Despite its initial problems, the medical community regards the PKU 
test as a gold standard for population based screening.47  Slowly, states 
began to look at other diseases also appropriate for testing.48  As the states 
widened the scope of their screening, questions arose about how to 
determine which disorders should be included within a screening panel.  
Different advisory committees came forward with criteria for determining 
whether the screening panel should include a particular disorder.  These 
criteria provide structure to the programs49 and have greatly impacted 
newborn screening programs in the United States.50  
B. The Criteria Developed in the United States to Determine Which 
Disorders to Include in a Screening Panel Are Necessary to Protect 
the Best Interests of the Newborn 
The criteria developed for newborn screening by advisory committees 
within the United States are necessary to protect the best interests of the 
child with regard to newborn screening.  Wilson and Junger published the 
first set of criteria addressing the issue of newborn screening in 1968.51  
Their intention was to assist public health organizations and policy-makers 
in determining how to bring treatment to those with previously undetected 
diseases while avoiding harm to those persons not in need of treatment.52  
By using these criteria, screening would occur only for disorders posing a 
significant threat to the infant’s health where a treatment is available in the 
event of a positive result.   
As screening programs developed, different organizations released 
their own criteria designed to help identify which disorders a screening panel 
should include.  In 1974, William K. Frankenburg53 addressed this issue and 
concluded that:54    
The availability of a suitable screening test does not justify 
screening for a disease unless the disease is important, 
                                           
47
  See PAUL, supra note 24, at 176; Kolata, supra note 42. 
48
  See Levy & Albers, supra  note 29, at 139. 
49
  D.A.C. Elliman, C. Dezateux & H.E. Bedford. Newborn and Childhood Screening Programmes: 
Criteria, Evidence, and Current Policy, 87 ARCHIVES DISEASE CHILDHOOD 6 (2002). 
50
  See Therrell, supra note 19, at 67. 
51
  J.M.G. WILSON & G. JUNGER, Principles and Practice of Screening for Disease, in PUB. HEALTH 
PAPERS No.34 (Geneva: World Health Organization 1968) [hereinafter WILSON & JUNGER]. 
52
  See id. for the criteria developed by Wilson & Junger 
53
  William K. Frankenburg, MD, MSPH, is Professor Emeritus of Pediatrics and Preventative 
Medicine at the University of Colorado School of Medicine. 
54
  William Frankenburg, Selection of Diseases and Tests in Pediatric Screening, 54 PEDIATRICS 612 
(1974). 
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relatively prevalent, and amenable to early treatment. . . .  
Screening which is carried out without knowledge and 
consideration of these criteria . . . may actually do more harm 
than good.55  
In 1975, the National Academy of Sciences also addressed the issue of 
which disorders to include in newborn screening.56  Their criteria focused 
more on the availability of treatment, including education, follow-up care, 
and counseling, as well as the public benefit gained from the inclusion of a 
test within the screening program.57  Another relevant change was the 
addition of informed consent58 as a critical aspect of any screening done 
upon a newborn.59 
The Institute of Medicine published the next set of criteria in 1994.60  
These focused on the benefit to the newborn rather than to the general 
public, as well as the ability to confirm diagnosis and the availability of 
treatment.61  The committee also noted that they did not believe “newborns 
should be screened using multiplex testing for many disorders at one time 
unless all of the disorders meet the principles described.”62 
Finally, in 1999 the Maternal and Child Health Bureau (“MCHB”)63 
responded to Congressional interest in newborn screening by providing 
financial support for the American Academy of Pediatrics (“AAP”) to 
convene a Newborn Screening Task Force.64  In 2000, this Task Force 
published a report recommending the introduction of new tests in a 
“carefully designed manner that facilitates evaluation of the risks and 
benefits of screening, including the efficacy of follow-up and treatment 
protocols.”65 
                                           
55
  Id. 
56
  See  Therrell, supra note 19, at 68-69. 
57
  Id.  
58
  See Section V(D) for more information of the requirement of informed consent within the U.S. 
59
  Id. 
60
  For the criteria developed by the IOM see Committee on Assessing Genetic Risks, Institute of 
Medicine, Assessing Genetic Risks: Implications for Health and Social Policy 5 (Lori B. Andrews et al., 
eds. 1994) [hereinafter IOM Report]. 
61
  Id. 
62
  Id. at 5. 
63
  The U.S. Congress established the MCHB (originally the Children’s Bureau) in 1912.  In 1935, 
they enacted Title V of the Social Security Act, authorizing the MCHB services programs and providing a 
foundation and structure for assuring the health of American mothers and children.  This organization is a 
bureau of the Health Resources and Services Administration under the U.S. Department of Health and 
Human Services.  See MCHB Home Page, http://mchb.hrsa.gov/about/default.htm (last visited Oct. 3, 
2005). 
64
  See AAP, supra note 33. 
65
  Id. 
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While the criteria in general have evolved throughout the years, no set 
has emerged as the benchmark for all states to follow.  As a result, there is a 
vast disparity in the number of disorders screened among the states,66 and 
children receive anywhere from four to thirty tests based solely upon where 
they are born.67  
While there is no one list of criteria that is universally followed 
among the states, there are two criteria that resonate throughout.  First, there 
should be full understanding of the disorder to allow for accurate testing and 
provide effective treatment for those found to have a positive test result.  
Second, the test should offer a benefit to the newborn.  Because these two 
criteria permeate all the lists developed, one may conclude that every state 
relied upon them to some degree when developing their screening panels.68   
Today, the development of new technology capable of testing multiple 
disorders from a single drop of blood is threatening the criteria upon which 
these programs have relied.  Testing with this technology allows healthcare 
providers to identify more disorders; but these disorders do not necessarily 
meet the criteria.  A full understanding of the technology itself, including the 
potential it provides for newborn screening, is necessary to grasp the legal 
and political implications of this change. 
III. MS/MS THREATENS THE SCREENING CRITERIA DUE TO ITS POTENTIAL 
TO SIGNIFICANTLY EXPAND THE SCREENING PANEL 
MS/MS, one of the primary advances in technology influencing 
newborn screening,69 has the potential to expand the screening panel by 
testing for more disorders with just one drop of blood.70  This expansion 
threatens the criteria used in the United States by encouraging expansion 
prior to fulfillment of the criteria.   
Scientists initially considered MS/MS for use in newborn screening 
based on its ability to rapidly screen a single drop of blood for multiple 
                                           
66
  Id. 
67
  Because of this disparity, many now advocate for a federal policy mandating the number of 
disorders included in newborn screening.  See generally, McCabe et al., supra note 3. 
68
  Throughout the remainder of this comment, I will refer to these as the “two criteria” for including 
a disorder on the screening panel. 
69
  Donald H. Chace, Thoedore A. Kalas & Edwin W. Naylor, Use of Tandem Mass Spectrometry for 
Multianalyte Screening of Dried Blood Specimens from Newborns, 49 CLINICAL CHEMISTRY 1797, 1799 
(2003) [hereinafter Chace et al.]. 
70
  See, American College of Medical Genetics/American Society of Human Genetics Test and 
Technology Transfer Committee Working Group, Tandem Mass Spectrometry in Newborn Screening, 2 
GENETICS IS MEDICINE 267 (2000) [hereinafter ACMG/ASHG Working Group]; H. Hannon et al., 
Outcomes from Tandem Mass Spectrometry (MS/MS) Workshops in the United States and the Performance 
Evaluation of MS/MS Laboratories, 34 SOUTHEAST ASIAN J. TROP. MED. & PUB. HEALTH 121, 121 (2003). 
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disorders.71  The screening consists of analyzing the quantity of amino 
acids72 and acylcarnitines73 present in the blood spot taken from the 
newborn.74  In the case of inherited metabolic diseases, specific enzymes 
that facilitate the breakdown of amino acids or the conversion of fat to 
energy simply do not function.75  The compound accumulates in the blood 
and tissue and becomes a poison to the child rather than a normal 
substance.76  MS/MS measures these compounds in order to determine if too 
much is present in the newborn’s blood, an indication of whether the child’s 
metabolic system is functioning properly.77  If an abnormal amount is 
present, the screeners can determine what particular disorder the child may 
possess based upon which molecule is in excess.78  In this way, healthcare 
workers use a single drop of blood to determine the health of a child with 
regard to multiple disorders. 
Advocates rationalize the use of MS/MS for newborn screening in a 
number of ways.  First, they point to the machine’s capability to screen for 
thirty or more metabolic disorders from one drop of dried blood.79  In this 
way, MS/MS significantly increases the potential of including more 
disorders in newborn screening programs.80  For certain metabolic disorders 
in which a treatment is known, early detection can result in a significant 
improvement in the health of the child.81  Furthermore, advocates argue that 
even if the treatment for a certain disorder is unknown, identification will 
still benefit the patient and family.82  Parents gain peace of mind in knowing 
the existence of the disorder and are better able to plan for the future.83  
                                           
71
  See AAP, supra note 33. 
72
  Donald H. Chace, A Layperson’s Guide to Tandem Mass Spectrometry in Newborn Screening, at 
http://www.savebabies.org/NBS/msms-chace.php (last visited Oct. 31, 2005) (on file with Journal) 
[hereinafter Layperson’s Guide] (amino acids are the “building blocks” of proteins). 
73
  Id. (acylcarnite exists when a carnitie, the “transportation system” for fats in and out the cell’s 
mitochondria, is attached to a fat indicating that it is functioning properly). 
74
  W. Harry Hannon & Scott D. Grosse, Using Tandem Mass Spectrometry for Metabolic Disease 
Screening Among Newborns: A Report of a Work Group, 50 MMWR 1 (2001). 
75
  See Chace, supra note 69. 
76
  See id. 
77
  See Hannon & Grosse, supra note 74. 
78
  See Chace, supra note 69. 
79
  See, e.g., Press Release, Mayo Clinic, Mayo Clinic Researcher Calls for Improved Newborn 
Screening Minnesota Method Accurate, Cost-Effective (Feb. 21, 2005), available at 
http://www.mayoclinic.org/news2005-rst/2683.html (last visited Oct. 3, 2005) (the doctor interviewed 
pointed out that MS/MS is able to screen for “upwards of 40 … genetic diseases”).  
80
  Id. 
81
  See Hannon & Grosse, supra note 74, at 2. 
82
  Id. 
83
  See Ellen Wright Clayton, Genetic Testing in Children, 22 J. MED. & PHIL. 233, 238 (1997). 
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Additionally, scientists argue analysis by MS/MS is more sensitive,84 
specific, and reliable than previous methods of newborn screening.85  For 
example, research has indicated that MS/MS has a false positive rate up to 
ten-fold lower for PKU screening than the best method previously 
available.86  This device has also proven to be very accurate in that it can 
measure a very small amount of material for the presence of a single 
compound with excellent precision.87  The performance rate for analysis is 
another rationale for its adoption in newborn screening, as the test takes only 
a matter of minutes from start to finish.88  For these reasons, proponents of 
MS/MS argue that states should adopt it for use in their newborn screening 
programs.89   
While the above rationales present a compelling argument for 
incorporation of MS/MS into newborn screening programs, their evaluation 
is not possible without also considering the negative impact of such an 
adoption.  One aspect of the technology advanced in opposition to its use for 
newborn screening is the cost.90  The instrument itself costs around $400,000 
per machine, but this expense alone is far from the total necessary to 
incorporate the technology into screening programs.91  States must also 
consider the cost of counseling and treatment as they are also an integral part 
of the programs.  In addition, scientists suggest that the use of MS/MS could 
increase the number of patients identified annually by fifty to one-hundred 
percent.92  These children will require follow-up testing, which can lead to 
expensive treatments and/or counseling for the affected family members.93  
This in turn will require an increase in physicians, nutritionists, and genetic 
counselors involved in newborn screening programs.94  Furthermore, while 
the method of screening is itself simple, analyzing the results is not.95  
                                           
84
  Sensitivity of testing refers to the ability of a test to pick-up a set factor, such as the abundance of 
a particular amino acid in the blood.  Specificity refers to the ability of the test to accurately report what 
amino acid it has detected. 
85
  See, e.g., AAP, supra note 37; V. Wiley et al., Newborn Screening – Is It Really That Simple?, 34 
SOUTHEAST ASIAN J. TROP. MED. & PUB. HEALTH 107, 107 (2003) (MS/MS has shown a sensitivity of 
95.9% and specificity of 99.8%). 
86
  See id.; see also ACMG/ASHG Working Group, supra note 70, at 267 (“MS/MS is more accurate 
than most methods now in use for newborn screening and would thus provide more specific and sensitive 
screening for [PKU]”). 
87
  See Layperson’s Guide, supra note 72.  
88
  See ACMG/ASHG Working Group, supra note 70, 267. 
89
  Id. 
90
  See Chace et al., supra note 69.  
91
  Id. 
92
  ACMG/ASHG Working Group, supra note 70, at 268. 
93
  See Hannon & Grosse, supra note 74, at 14. 
94
  Id. 
95
   See Layperson’s Guide, supra note 72. 
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Accurate analysis of the data requires extensive training, which further adds 
to the expense of its incorporation.96 
In addition to cost, those who oppose adopting MS/MS for newborn 
screening cite the lack of knowledge about the disorders themselves.97  For 
example, the specificity of the technology may lead to identification of 
carriers who will never become symptomatic due to differing degrees of 
severity within the disorder itself.98  Full understanding of the disorder is 
necessary in order to differentiate between those who will suffer from it and 
those who merely carry the trait.99  This issue leads many to caution against 
outright adoption of MS/MS into newborn screening programs until more 
knowledge is available about the disorders themselves.100 
Despite the above-mentioned drawbacks of incorporating MS/MS, 
thirty-four states101 have already incorporated it into their newborn screening 
programs.102  States rationalize this adoption by referring to the vast number 
of disorders MS/MS can detect.103  In addition, advocacy groups have 
exerted significant pressure on policy-makers to adopt this technology,104 
undoubtedly affecting the incorporation of the technology in many states.105  
Due to the pressure from such interest groups, many states are expanding 
their panels to include disorders never before incorporated into newborn 
screening.106   
This technology and the resulting expansion of newborn screening is 
changing the face of newborn screening in the United States and worldwide. 
The increasing ability to detect disorders pushes the limits of already 
established criteria.107  Questions remain as to whether the criteria should, or 
must, change due to the adoption of MS/MS.  
                                           
96
  See ACMG/ASHG Working Group, supra note 70, at 268. 
97
  See Wilcken et al., supra note 12, at 2304. 
98
  See Hannon & Grosse, supra note 74, at 14. 
99
   See Wilcken et al., supra  note 12, at 2304. 
100
  See, e.g., supra note 74, at 14. 
101
  Three of these states — California, Oklahoma, and Missouri — have mandated the screening but it 
is not yet implemented.  NATIONAL NEWBORN SCREENING STATUS REPORT (Oct. 21, 2005), http://genes-r-
us.uthscsa.edu/nbsdisorders.pdf  (last visited Oct. 1, 2005). 
102
  Id. 
103
  Chace et al., supra note 69.  
104
  See Wilcken et al., supra note 12, at 2309. 
105
  See id. 
106
  In 1998, state mandatory panels screened from 0 to 8 disorders, while today, some states screen 
for more than 30, with North Dakota screening for a total of 38 disorders, 32 of which are screened using 
MS/MS.  This startling increase indicates the effect MS/MS technology has had on the screening panel.  Id. 
107
  Brink, supra note 7 (Lainie Ross, Associate Professor of Pediatrics and Clinical Director of the 
MacLean Center of Clinical Medical Ethics at the University of Chicago stated, “[w]e may be creating this 
whole community of people who have a diagnosis, some of whom never get sick.”). 
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In addressing these issues, the United States can look to Australia, 
which expanded newborn screening through the use of MS/MS.  A close 
evaluation of the results of the screening within that country is helpful in 
determining what, if any, steps the United States should take in this area. 
IV. AUSTRALIA’S USE OF MS/MS FOR NEWBORN SCREENING REVEALS 
PROBLEMS IN SUCH APPLICATION OF THE TECHNOLOGY  
An Australian study utilizing MS/MS for newborn screening sheds 
light on the problems associated with using this technology.  Specifically, 
such screening will result in the false identification of those who will never 
be affected by a particular disorder.108  In 1998, the New South Wales 
newborn screening program became the first to use MS/MS.109  Over the 
next four years, the state laboratory tested 362,000 newborns for thirty-one 
inborn errors of metabolism using this technology.110  The screeners 
compared these results to the previous rate of clinical diagnosis for four 
preceding four-year periods.111  At the end of the four years, screening had 
identified and diagnosed fifty-seven newborns — forty-eight through 
screening and six through clinical diagnoses occurring at or before the time 
the screening results were available.112  Seven other patients received 
clinical diagnosis after the testing period.113  Two patients born to mothers 
with a known risk who also had affected siblings declined screening.114 
In comparing the results to the prior history of clinical diagnoses for 
disorders within newborns, the researchers found that this screening 
diagnosed two disorders at a significantly higher rate:115 medium-chain and 
short-chain acyl-coenzyme A (“CoA”) dehydrogenase deficiency.116  While 
there is no clear evidence whether identification of the short-chain variant 
will be clinically useful,117 identification of the medium-chain variant 
(“MCADD”) may prevent death among infants. 
                                           
108
  See Wilcken et al., supra note 12, at 2309. 
109
 See Hannon & Grosse, supra note 74, at 33 (reporting on Bridget Wilcken & Veronica Wiley, 
Tandem Mass Spectrometry in the New South Wales Newborn Screening Program for Metabolic Disease 
Screening Among Newborns Workshop (June 2000)). 
110
  Wilcken et al., supra note 12, at 2308. 
111
  Id. at 2308. 
112
  Id. (the 6 that were identified clinically are also included in the 48 identified through the 
screening). 
113
  Id. at 2309. 
114
  Id. at 2309-10.   
115
  Id. at 2309. 
116
  Id. 
117
  Id. at 2309-11. 
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MCADD is a rare disease caused by the lack of an enzyme required to 
convert fat to energy.118  Exposure of a child with MCADD to a period of 
fasting can result in serious injuries or even death119 resulting from a build-
up of fatty acids in the blood.120  Scientists estimate that the first episode of 
fasting is fatal in thirty to fifty percent of patients.121  Treatment for this 
disorder requires avoiding these periods of fasting.122 
Following PKU, MCADD was the most commonly detected disorder 
in the Australian study.123  The results of this study indicated the disorder has 
a prevalence of approximately one in 19,000.124  However, many patients 
identified by the screening as having the disorder remained healthy.125  This 
absence of symptoms accounts for the significant difference between 
children diagnosed through the MS/MS screening versus those diagnosed 
clinically in the period prior to the study.126  The children who remained 
undiagnosed under the previous model appear to have a different form of the 
disease that either presents itself in a significantly milder fashion or perhaps 
is completely benign.127  However, when MS/MS is used, there is no way to 
differentiate these patients from those who are indeed at risk.128  For this 
reason, physicians must treat all patients receiving a positive diagnosis as if 
they are at risk, even though the child may develop symptoms.129  The 
falsely identified children and their parents will be required to undergo 
                                           
118
  See Save the Babies Through Screening Foundation, Inc., Medium Chain Acyl-CoA 
Dehydrogenase Deficiency (MCADDD), at http://www.savebabies.org/diseasedescriptions/mcadd.php (last 
visited Oct. 4, 2005); Neil A. Holtzman, Expanded Newborn Screening – How Good is the Evidence, 290 
JAMA 2606 (2003).   
119
  See Washington State Department of Health, Newborn Screening: Medium Chain Acy-coA 
Dehydrogenase Deficiency (MCADD), available at http://www.doh.wa.gov/EHSPHL/PHL/Newborn 
/mcadd.htm (last visited Oct. 4, 2005). 
120
  See Karl S. Roth, Medium-Chain Acyl-CoA Dehydrogenase Deficiency, in E-MEDICINE (Edward 
Kaye et al., eds. 2003), available at http://www.emedicine.com/ped/topic1392.htm (last visited Oct. 4, 
2005). 
121
  ACMG/ASHG Working Group, supra note 70, at 2671. 
122
  See Department of Public Health for the State of Connecticut, Genetics Newborn Screening 
Program: MCADD Family Fact Sheet (Jan. 19, 2005), available at http://www.dph.state.ct.us/BCH/NBS/ 
Resources/mffs.pdf (last visited Oct. 4, 2005). 
123
  See Wilcken et al., supra  note 12, at 2311; V. Wiley et al., Newborn Screening with Tandem Mass 
Spectrometry: 12 Months’ Experience in NSW Australia, 88 ACTA PAEDIATRIC SUPPLEMENT 48 (1999). 
124
  See Kevin Carpenter et al., Evaluation of Newborn Screening for Medium Chain Acyl-CoA 
Dehydrogenase Deficiency in 275,000 Babies, 85 ARCHIVE OF DISABLED CHILD FETAL NEONATAL 
EDUCATION F105 (2001). 
125
  See Wilcken et al., supra note 12, at 2311. 
126
  Id. 
127
  Id. 
128
  BS Andresen, et al., The Molecular Basis of Medium-chain Acyl-CoA Dehydrogenase (MCADD) 
Deficiency in Compound Heterozygous Patients: Is There Correlation Between Genotype and Phenotype, 6 
HUMAN MOLECULAR GENETICS 695 (1997). 
129
  See Wilcken et al., supra note 12, at 2311. 
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genetic counseling and a stringent management plan in order to prevent a 
risk that was never a reality to the child.130  The Australian scientists 
themselves acknowledged that “decisions on expansion of the newborn 
screening programmes to include [MCADD] deficiency should be taken in 
the knowledge that this is a complex disorder, and that not all cases 
discovered by newborn screening may be at risk.”131 
This overly-broad treatment due to insufficient knowledge of a 
particular disorder is not a new development within newborn screening 
programs — it was also present in the early days of PKU screening.132  
While the researchers during that time eventually gained enough information 
to lower the false-positive results, the interim period saw severe 
consequences for many children falsely identified as diseased.133  The fact 
that a different disorder is encountering similar problems indicates that states 
should use caution before proceeding with such screening in order to avoid 
this result for even more disorders. 
Despite the issues surrounding diagnosis of children at risk for 
MCADD, the New South Wales program successfully demonstrated that 
MS/MS detects more cases of inborn errors of metabolism than clinical 
diagnosis.134  Like MCADD, however, many of the other thirty-one 
disorders included in the screening are complex and not yet fully 
understood.  Therefore, not all infants receiving positive results will actually 
be at risk as some will never become symptomatic.135  Until scientists 
conduct more studies of these disorders, this result is inevitable.136 
V. THE UNITED STATES SHOULD BE CAUTIOUS WHEN INCORPORATING 
MORE DISORDERS INTO THEIR SCREENING PANELS  
The results of the Australian study indicate that the United States, and 
others considering the usage of MS/MS to expand newborn screening 
panels, should proceed cautiously prior to incorporating new disorders into 
their programs.  In the United States, a direct comparison to the results of the 
Australian study is possible due to a close resemblance between the newborn 
screening programs of these two countries. 
                                           
130
  See Carpenter, supra note 124, at F105. 
131
  Id. at F108. 
132
  Clayton, supra note 20, at 106. 
133
  Id. 
134
  Wilcken et al., supra note 12, at 2304. 
135
  Carpenter et al., supra note 124, at F105. 
136
  Id. 
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A. Similarities Between the Australian and the United States’ Newborn 
Screening Programs Provide for Accurate Comparisons of the 
Methods Used for Testing 
The United States can learn from the results of the Australian study 
due to similarities between the newborn screening programs in these two 
countries.  Like the United States, Australia first established newborn 
screening programs in the late 1960s137 and implemented them through state-
wide programs around 1970.138  Australia consists of six states and two 
territories,139 each of which is responsible for coordinating newborn 
screening services through centralized state laboratories. 140  This resembles 
the state-by-state approach currently in use in the United States.  In addition, 
the Australian program is fully publicly funded;141 much like its counterpart 
in the United States where each state’s Department of Health provides most 
of the funding.142  One final similarity is the method both countries use for 
developing the screening panel.  In Australia, a joint subcommittee of the 
Human Genetics Society of Australia (“HGSA”) and the Division of 
Paediatrics of the Royal Australasian College of Physicians (“RACP”) 
generates policy statements recommending screening policies applicable to 
all states and New Zealand.143  The individual states then use these 
recommendations to determine the specifics of their program, including the 
methods used and disorders included in the screening panel.144  In this way, 
the HGSA Policy Statements serve a similar function to the criteria 
developed by different advisory committees within the United States; they 
offer guidance to lawmakers in structuring the newborn screening 
programs.145  Overall, the similarities between these two programs allow 
                                           
137
 See HGSA Policy Statement 2004, supra note 18. 
138
 Diane Webster, Newborn Screening in Australia and New Zealand, 34 SOUTHEAST ASIAN J. TROP. 
MED. & PUB. HEALTH 69, 69 (2003). 
139
 The states are: New South Wales, Queensland, South Australia, Tasmania, Victoria, and Western 
Australia; the territories are: Australian Capital Territory and Northern Territory.  See Australian 
Government: Department of Foreign Affairs and Trade, Australia: An Introduction, available at 
http://www. dfat.gov.au/facts/intro.html (last visited Oct. 4, 2005). 
140
 HGSA Policy Statement 2004, supra note 18.  
141
 See Webster, supra note 138. 
142
  Id. 
143
  Id. 
144
  Id. 
145
  In the most recent HGSA Policy Statement (2004), the committee listed the following criteria as 
factors that should be present for a disorder to be included within the newborn screening program: “(1) 
there is a benefit for the baby from early diagnosis (benefit to the family may also benefit the baby); (2) the 
benefit is reasonably balanced against financial and other costs; (3) there is a reliable test suitable for 
newborn screening; (4) there is a satisfactory system in operation to deal with diagnostic testing, 
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lawmakers in the United States to analyze the results of the Australian study 
when assessing the development of the programs within their state. 
B. The Australian Study Demonstrates That Many of the Disorders 
Proposed for Addition into Newborn Screening in the United States 
Fail to Meet the Criteria Traditionally Relied Upon 
When lawmakers in the United States assess their newborn screening 
programs in conjunction with the Australian study utilizing MS/MS, they 
will recognize that such technology is not appropriate for the screening of 
many disorders due to the failure of such disorders to meet the necessary 
criteria.146  In many states, however, this expansion has already occurred or 
is in the process of occurring.147  For these states, the issue is whether 
legislators need to make changes to the current programs in order to 
accommodate this expansion.  An evaluation of these disorders using the two 
criteria discussed above indicates that care is necessary prior to their 
incorporation into the screening panel.  
Now that scientists know MS/MS detects more disorders than 
previous screening methods,148 the question is whether these new disorders 
meet the old criteria utilized by the states. 149  Closer evaluation reveals 
problems in this regard.  One may argue that since these disorders have not 
previously been included in screening they must not meet the criteria.  
However, scientists rationalize the expansion of screening to include these 
                                                                                                                              
counseling, treatment and follow-up of patients identified by the test.”  Id.; HGSA Policy Statement 2004, 
supra note 18.  
146
  See supra  Part II(B).   
147
  See NATIONAL NEWBORN SCREENING STATUS REPORT (2005), supra note 101.  Currently, only 11 
states, including the District of Columbia, do not use this technology at all.  It is mandated in 34 states (in 3 
it has not yet been implemented),  part of universal pilot programs in 4 states, and not mandated, but 
available through pilot programs or by request, in 7 states.  Overlap occurs because in some states testing is 
mandated while in others it is available through pilot programs.  For example, in New Jersey, 11 disorders 
are mandated while 8 are not mandated but available through pilot programs or by request.  New Jersey is 
therefore included in both of these subgroups.  Id.; see also P. Rinaldo, Recent Developments and New 
Applications of Tandem Mass Spectrometry in Newborn Screening, 16 CURRENT OPINION PEDIATRICS 427, 
427 (2004) (“newborn screening in the United States is undergoing a rapid expansion driven by the 
introduction of tandem mass spectrometry in at least 34 state programs); Alissa Johnson,  Newborn Genetic 
and Metabolic Disease Screening, NATIONAL COUNCIL OF STATE LEGISLATURES (2005), available at 
http://www.ncsl.org/programs/health/genetics/newborn.htm (last visited Oct. 4, 2005) (“[r]ecent advances 
in technology have enabled some states to add a substantial number of conditions to the newborn screening 
panel in a relatively short timeframe”). 
148
  See Wilcken et al., supra note 12, at 2304. 
149
  For a list of disorders proposed for screening through MS/MS, see HGSA Policy Statement 2004, 
supra note 18, for Australia, and March of Dimes, Recommended Newborn Screening Tests: 29 Disorders, 
at http://www.marchofdimes.com/professionals/681_15455.asp (last visited Oct. 31, 2005) [hereinafter 
March of Dimes] for the U.S. 
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disorders by the increased rate of detection.  The implications of such a 
change are apparent when evaluating one of these disorders in detail. 
In the first Australian study on the usage of MS/MS for newborn 
screening, the researchers concluded that the greatest increase in the rate of 
diagnosis from the old system to the new one occurred with regard to 
MCADD.150  A United States study in New England later reported similar 
results.151  This disorder is consequently one of the primary rationales for 
utilizing MS/MS in newborn screening.  However, when compared against 
the current criteria for adding a disorder to the screening panels within the 
United States, it is clear that MCADD fails to meet the two required factors 
— knowledge of the disorder and benefit to the child.152 
First, scientists lack full understanding of this disorder.  The 
significant increase noted in the Australian study of children identified with 
MCADD through MS/MS, versus those previously identified, indicates that 
at least some of these children have different genotypes for the disorder than 
those associated with severe health episodes or sudden death.153  This 
increase is due to over-detection by the tandem mass spectrometer resulting 
from a lack of knowledge on the different genotypes associated with the 
disorder.154  Instead of detecting only the children at severe risk, the 
screening picks up those with benign or mild forms of the disorder who will 
never develop symptoms.155  More research is necessary to allow 
differentiation between these two groups.  Until the genotype associated 
with the disorder is clearly understood, healthy children will continue to be 
labeled as diseased – a diagnosis which could potentially affect many 
aspects of their life.156  The criteria require full understanding of a disorder 
prior to their incorporation in screening programs for precisely this reason.   
                                           
150
  Wilcken et al., supra note 12, at 2308. 
151
  Waisbren et al., supra note 11, at 2567, 2570-71. 
152
  See supra Part II(B). 
153
  See Peter T. Clayton et al., Screening for Medium Chain Acyl-CoA Dehydrogenase Deficiency 
Using Electrospray Ionization Tandem Mass Spectrometry, 79 ARCHIVES DISEASE CHILD 109 (1998); see 
also Waisbren et al., supra note 11, at 2570-71. 
154
  Holtzman,  supra note 118, at 2606 (the increase in rate of detection seems to be due to MS/MS 
overdetection because of failure to distinguish between infants at risk).  See also Andresen et al., supra note 
128, at 695 (the genotype/phenotype correlation in MCADD is not clear).  Similar over-detection was 
discovered with Isovaleric Acidemia (IVA).  MS/MS identified 19 subjects with a genetic mutation, and 
then found six healthy older siblings with identical genotype and biochemical evidence of IVA.  These 
findings indicate there is a mild and potentially asymptomatic phenotype of IVA.  Regina Ensenauer et al., 
A Common Mutation is Associated with a Mild, Potentially Asymptomatic Phenotype in Patients with 
Isovaleric Acidemia Diagnosed by Newborn Screening, 75 AM. J. HUM. GENETICS 1136, 1137 (2004).   
155
  See generally Carpenter, supra note 124. 
156
  Clayton, supra note 20, at 106-109 (suggesting that this mislabeling can cause disruption in the 
development of the parent-child relationship, and also may result in employment or insurance 
discrimination against the child.). 
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Second, there is no clear benefit to the child.  The large number of 
children identified from screening who developed no symptoms indicates 
that the risk is not as high as was previously believed.157  In reality, not all 
children with this genotype are at risk.  Since they are not at risk, the testing 
is not beneficial to them.  MCADD therefore fails with regard to this 
criterion. 
Those advocating the use of MS/MS in newborn screening argue that 
this technology will allow for detection of additional disorders from a single 
screen.158  MCADD is one of the strongest examples in this regard due to the 
fact research has shown MS/MS identifies more patients with this 
disorder.159  However, the prior discussion demonstrates that such screening 
presents new issues not encountered in the previous screening programs 
based upon the failure of this disorder to meet the criteria currently used.  If 
MCADD presents the best results, the other disorders proposed for 
adoption160 will also fail to fit within these criteria.   
1. Adapting Criteria to Incorporate More Disorders into Newborn 
Screening Programs Is Incongruent with Legal Principles of the 
United States 
In light of differences in American legal principles, the United States 
must differ from Australia in the method used to allow for inclusion of new 
disorders within American states’ screening programs.  Australia has 
resolved the problems faced in the United States regarding the adoption of 
these new disorders through a slight modification to their criteria, but a 
similar change is not possible within the United States because of the 
differences between the criteria utilized by the two countries.  While the 
United States requires full understanding of the disorder prior to 
incorporation in a screening panel, the HGSA Policy Statement does not 
include such a requirement.161  This absence avoids the issue encountered in 
the United States arising from the requirement for full understanding of the 
various genotypes of a disorder, such as MCADD, prior to adding it to the 
                                           
157
  See Carpenter et al., supra note 124, at F1008 (“not all cases discovered by newborn screening 
may be at risk.”). 
158
  See Laypersons Guide, supra note 72. 
159
  See Wilcken et al., supra note 12. 
160
  Another example is 3-Methylcrotonyl-CoA carboxylase deficiency (“3MCC”), which is described 
as a disorder that can lead to brain damage, seizures, liver failure and death, or may result in no symptoms 
at all.  Furthermore, while treatment may be helpful, a positive result on the screening test “could be related 
to abnormal metabolites in the mother and not the baby.” March of Dimes, supra note 149. 
161
  HGSA Policy Statement 2004, supra note 18.  
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states’ screening panels.  The Australian states have not had to address this 
issue in adding MCADD, as well as other disorders, to its screening panels. 
Additionally, Australian policy-makers have made slight but 
significant adjustments to their criteria in order to allow incorporation of 
such disorders into newborn screening.  The first criterion in the 1999 HGSA 
Policy Statement asserts that “newborn screening is recommended provided 
that . . .  [t]here is a benefit for the individual from early diagnosis.”162  
However, by 2004, this requirement changed to state: “[t]here is benefit for 
the baby from early diagnosis (benefit to the family may also benefit the 
baby).”163  Rather than requiring a benefit to the child alone, Australia now 
allows for the addition of a disorder if it offers benefit to the family.164  If the 
benefit need not be to the child alone, this implies that the child also need 
not be at risk, as is required in the United States.  This change, however, 
allows for the addition of almost any genetic disorder to the newborn 
screening panel because the family of the child will likely benefit by 
acquiring knowledge regarding their own genetic make-up.  For example, 
such knowledge can assist parents, and other relatives, in future decisions 
regarding child-bearing.  Therefore, it is apparent that Australia has greatly 
expanded the scope of its newborn screening programs to incorporate 
numerous new disorders based upon this single change in the criteria. 
2. The United States Must Either Change Its Criteria or Limit the Usage 
of MS/MS  
If the American states intend to continue using MS/MS for newborn 
screening, there are two ways in which they can address the issue of new 
disorders that fail to meet the current criteria.  First, the states could choose 
to keep the criteria and simply not allow incorporation of new disorders into 
the screening panel until they meet all of the necessary criteria.  Second, the 
states may decide to change the criteria in order to incorporate these 
disorders at the present time, as was done in Australia. 
                                           
162
  HGSA Policy Statement 1999, supra note 16. 
163
  HGSA Policy Statement 2004, supra note 18 (emphasis added). 
164
  In an e-mail received from Ms. Diane Webster, chairperson of the HGSA-RACP Newborn 
Screening Committee, this change in wording was explained as follows: “It was clear that there was less 
worry to the family if the cause of the failing to thrive was known, and of course once the presence of an 
autosomal recessive disorder is known in a family they can make better informed reproductive choices and 
the committee wanted to word the policy so benefits of this type (not directly to the individual) could be 
validly considered.” E-mail from Diane Webster, Chairperson of the Joint HGSA-RACP Newborn 
Screening Committee, to Lauren Fisher, Law Student, University of Washington School of Law (Apr. 27, 
2005) (on file with Journal). 
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The second option is not viable for the United States.  Australia 
amended its criteria to allow for testing of a child so long as it offers benefit 
to either the child or the child’s family.  This enables testing of one 
individual in order to benefit another.  A similar change in the United States 
is contrary to American values in that it violates the principle of personal 
autonomy.165  Therefore, such an amendment would not be legally 
acceptable in the United States. 
The remaining option for the United States is to leave their system 
unaltered, thereby choosing not to expand the screening panel until a 
disorder fulfills the criteria.  There are a number of problems associated with 
this option.  First, and perhaps most importantly, one of the primary 
rationales for using MS/MS is its ability to screen for a large number of 
disorders from a single drop of blood.166  Restricting such broad application 
of MS/MS reduces the value of an expensive piece of medical equipment.  
States must then decide whether to budget for MS/MS when previously used 
screening methods can already test for the approved disorders.  Only the 
states themselves can make this determination through a cost-benefit 
analysis. 
The second issue raised is whether the states will be able to refrain 
from adding disorders until they meet the criteria.  Once this technology is in 
place, pressure from advocacy groups may lead state policy-makers to 
abandon the traditional criteria in order to add new disorders to the screening 
panel.  In the past, advocacy groups have played a significant role in the 
expansion of newborn screening programs by lobbying for the inclusion of 
more genetic disorders within the screening panel.167  In recent years, such 
lobbying has proved effective, and there is a significant trend in the states to 
increase the screening panel.168  Therefore, it is not only safe to assume that 
the adoption of this technology will lead to an increase in the number of 
disorders tested; it is nearly a proven fact.169  Even if states do not intend to 
                                           
165
  See Washington v. Glucksberg, 521 U.S. 702, 777 (1997) (Souter, J., concurring) (there is a 
constitutionally protected liberty interest in bodily integrity and the right to determine what medical 
treatment shall be accepted or refused).  
166
  Cf. ACMG/ASHG Working Group, supra note 70, at 267. 
167
  See Holtzman, supra note 118; see also March of Dimes, supra note 149; Save Babies Through 
Screening Foundation Home Page, at http://www.savebabies.org  (last visited Oct. 4, 2005) (Save the 
Babies is an organization formed by parents of disabled children and an influential advocacy group that has 
exerted pressure upon legislators to add more disorders to newborn screening). 
168
  From 1998 to 2004, some U.S. states increased their screening panel from less than 5 to more than 
30.  This significant increase is due to the incorporation of MS/MS technology into these programs and 
shows the impact advocacy groups have over the legislative process in this area.  NATIONAL NEWBORN 
SCREENING STATUS REPORT, supra note 101. 
169
  For a complete list of all the disorders currently mandated by states for inclusion in the newborn 
screening program, see id. 
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expand the screening panel beyond those disorders meeting the criteria, such 
expansion may be inevitable.170   
Given that many states have already incorporated numerous new 
disorders into their newborn screening panels, states should not mandate this 
screening until the disorders meet the criteria previously required.171  For 
many disorders, such as MCADD, this requirement would mean increasing 
the knowledge of the disorder itself to raise the false-positive rate to an 
acceptable level.  Some states have implemented pilot programs to gain this 
knowledge without mandating screening.172  However, this action also raises 
legal issues policy-makers must address before moving forward with such 
programs. 
C. The Informed Consent Requirements in the United States Restrict 
Expansion of Newborn Screening Through MS/MS  
The doctrine of informed consent further restricts expansion of 
newborn screening.  Traditionally, every disorder included within screening 
caused a severe risk to the health of the child, as was required to meet the 
criteria.  A severe health risk created a compelling reason to require the 
screening.  However, by expanding the scope of the screening panel to 
include disorders not posing as great a threat, the use of MS/MS reduces the 
compelling nature of the need to screen. 
Informed consent developed out of the 1946 Nuremberg Code173 and 
has become one of the cornerstones of our healthcare system.  This principle 
requires healthcare providers to receive voluntary and fully informed 
consent from a patient, or that patient’s representative, prior to performing 
any treatment.174  Newborn screening programs, however, have accompanied 
the emergence of an alternate method of consent different than full and 
voluntary consent of the parent or guardian.  While all states currently have 
                                           
170
  See William J. Rhead & Mira Irons, The Call from the Newborn Screening Laboratory: 
Frustration in the Afternoon, 51 PEDIATRIC CLIN. NORTH AM. 803, 804 (2004) (observes that some 
disorders have been added to newborn screening programs in the United States without researchers 
knowing if there is a true benefit to early diagnosis and treatment, which is one of the criteria traditionally 
used for including a disorder in the screening panel). 
171
  For states already mandating screening of disorders that do not meet the criteria, policy-makers 
should at least discuss the implications of such policy and make adjustments they deem appropriate. 
172
  See NATIONAL NEWBORN SCREENING STATUS REPORT, supra note 101 (Florida, Louisiana, 
Maryland, Massachusetts, Montana, Nebraska, New Jersey, Oregon, Pennsylvania, South Dakota, Texas 
and Utah currently use pilot programs in their newborn screening programs). 
173
 See Risk and Vulnerable Groups, 4 ENCYCLOPEDIA OF BIOETHICS 2365, 2368 (3d ed., Stephen G. 
Post ed.,  2005) (“[t]he voluntary consent of a human subject is absolutely essential”). 
174
  See, e.g., Canterbury v. Spence, 464 F.2d 772, 780 (D.C. Cir 1972.) (“[t]rue consent to what 
happens to one’s self is the informed exercise of a choice, and that entails an opportunity to evaluate 
knowledgeably the options available and the risks attendant upon each.”) 
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statutes requiring newborn screening,175 only Wyoming176 and Maryland177 
require informed consent by the parents prior to screening.178  All others, 
with the exception of South Dakota,179 have an “opt out” policy180 under 
which parents must explicitly refuse screening in order to prevent it from 
occurring.181  In the majority of states, parents must base this refusal upon 
specific enumerated reasons, such as religion.182  However, many states deny 
parents the opportunity to “opt out.”183  Research has indicated these states 
rarely present parents with an opportunity to refuse testing.184  Instead, 
healthcare workers inform the parents about the testing only after it has 
occurred.185   
The justification for allowing states to perform newborn screening 
without the explicit informed consent of the parent is that parents do not 
have the authority to forego effective treatment for their child when that 
child has a life-threatening condition.186  Since all of the disorders 
traditionally incorporated into the newborn screening panel were both life-
threatening and amenable to treatment, the compelling interest of protecting 
the health of the child outweighed the infringement upon the fundamental 
right of the parent.187  States now face the question of whether the current 
                                           
175
  Cynthia E. Fruchtman & Francis C.J. Pizzulli, Ethical Aspects of Genetic Testing, 20 WHITTIER L. 
REV. 411, 415 (1998). 
176
 WYO. STAT. ANN. § 35-4-801(c) (1977) (“Informed consent of parents shall be obtained) 
(emphasis added). 
177
  MD. CODE ANN., [Health] § 13-109(e)(2) (1982). 
178
  See AAP Policy Statement, supra note 23.  See also, Elaine H. Hiller et al., Public Participation in 
Medical Policy Making and the Status of Consumer Autonomy: The Example of Newborn Screening in the 
United States, 87 AM. J. PUB. HEALTH 1280, 1283 (1997). 
179
  S.D. CODIFIED LAWS § 34-24-17 (1973). 
180
  For an example of legislation setting forth an “opt out” policy, see Washington’s applicable 
legislation at WASH. REV. CODE § 70.83.020. 
181
  See American Academy of Pediatrics: Committee on Bioethics, Policy Statement: Ethical Issues 
with Genetic Testing in Pediatrics, 107 PEDIATRICS 1451 (2001), available at 
http://www.aap.org/policy/re9924.html (last visited Oct. 5, 2005) [hereinafter AAP Policy Statement]. 
182
  See  Katherine L. Acuff, Prenatal and Newborn Screening: State Legislative Approaches and 
Current Practice Standard, in AIDS, WOMEN AND THE NEXT GENERATION – TOWARDS A MORALLY 
ACCEPTABLE PUBLIC POLICY FOR HIV TESTING OF PREGNANT WOMEN AND NEWBORNS 121, 134-162 
(Ruth R. Faden et al., eds., Oxford University Press 1991) (listing screening statutes and their applicable 
opt out requirements). 
183
  See Fruchtman & Pizzulli, supra note 175, at 416. 
184
  Id. 
185
  See id.  
186
  See AAP Policy Statement, supra note 181; George C. Cunningham, Balancing the Individual’s 
Right to Privacy Against the Need for Information to Protect and Advance Public Health, in GENETIC 
SCREENING FROM NEWBORNS TO DNA TYPING 210 (Bartha Maria Knoppers & Claude M. Laberge eds., 
1990).   
187
  See, e.g., Parham v. J.R., 442 U.S. 584, 602 (1979) (parents have a constitutionally protected right 
to obtain needed medical treatment for their child). 
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“opt out” method should, or must, change as they begin using MS/MS to 
screen newborns.   
Australia serves as an example of how to implement informed consent 
within these programs.  Section 4.1 of the HGSA Policy Statement of 2004 
states: “[p]arents should be informed of the availability of testing.  If after 
discussion the parents refuse to have their newborn tested, they should sign a 
statement that they are fully informed about the test and the consequence of 
not testing.”188  The committee amended this provision from the 1999 
version which provided that “[t]he individual responsible should ensure that 
parents are given information about the screening prior to the test being 
taken.”189  This amendment indicates that Australia tightened its informed 
consent requirements due to the incorporation of MS/MS into the programs.  
Instead of a parent merely needing to receive information about the 
screening, states now guarantee a full discussion regarding the screening 
program’s affect on their child.  The use of MS/MS has therefore led to a 
more meaningful consent requirement in Australia. 
In the United States, a similar change is necessary based on the 
incorporation of this technology.  While the current opt out policy was 
justifiable with regard to the traditional disorders, the addition of new 
disorders to the screening panel removes the compelling nature of the testing 
for at least some of the disorders.  Due to the current lack of understanding 
surrounding these new disorders, physicians can no longer assume that the 
children identified are in a life-threatening position.  Therefore, the state 
interest no longer outweighs the fundamental right of the parents, because it 
lacks the compelling nature required.  States should therefore mandate some 
form of consent for this testing to satisfy the legal requirements of the 
American healthcare system.190   
For the United States, merely requiring informed consent does not 
completely address the legal problems implicated by this new program.  In 
order to learn more about these disorders, screening must occur on a large 
number of children to identify those affected.  In fact, four states have 
already incorporated universal pilot programs on all newborns. 191  Gaining 
the requisite information regarding the disorders will depend upon such pilot 
programs because otherwise, the sample population will not be large enough 
                                           
188
  HGSA Policy Statement 2004, supra note 18. 
189
  HGSA Policy Statement 1999, supra note 16. 
190
  See Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972); Truman v. Thomas, 611 P.2d 902 (Cal. 
1980). 
191
  NATIONAL NEWBORN SCREENING STATUS REPORT, supra note 101 (the 4 states are Louisiana, 
Maine, Massachusetts, and Oregon). 
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to produce any viable results.  Therefore, states will need to implement 
universal pilot programs in order to identify subjects to study with the hope 
of increasing knowledge of the disorder itself.  These universal pilot 
programs are more likely to be characterized as research programs rather 
than medical procedures. 
D. Newborn Screening Pilot Programs May Potentially Be Classified As 
Research Which Further Prevents Expansion of the Screening Panel  
One final hurdle facing the expansion of the screening panel after 
adoption of MS/MS is the possibility that such programs will be classified as 
research.  Increased understanding of many of the disorders proposed for 
screening is required for the disorders to meet the criteria utilized by the 
states’ lawmakers.  Because they are so rare, scientists cannot effectively 
study these disorders unless screening occurs on an extremely large number 
of individuals.192  For this reason, many advocates of the technology have 
recommended implementing universal pilot programs193 in order to utilize 
the technology to identify affected children, thus allowing further study on 
the disorder itself.194  As was previously mentioned, four states currently 
practice universal screening195 on all babies under pilot programs designed 
to study these rare disorders.196  Such programs raise the issue of whether 
policy-makers should require specific informed consent from parents for this 
type of testing and whether the consent of the parent is sufficient. 
The United States’ scientific community defines research as “a 
systematic investigation, including research development, testing and 
evaluation, designed to develop or contribute to generalizable 
knowledge.”197  Universal pilot programs potentially meet this definition.  In 
the United States, however, there is a separate set of requirements for 
                                           
192
  The incidence rates of some of these disorders are:  Citrullinemia – less than 1 in 100,000, 
Argininosuccinic academia – less than 1 in 100,000, Tyrosinemia type I – less than 1 in 100,000, Maple 
syrup urine disease – less than 1 in 100,000, isovaleric academia – less than 1 in 100,000.  See March of 
Dimes, supra note 149. 
193
  Australia also recommends such pilot programs.  Section 5.2 of the 2004 HGSA Policy Statement 
provides that “[p]ilot studies should be undertaken to demonstrate the safety, effectiveness, validity and 
clinical utility of tests for additional disorders and new testing technologies.”  See HGSA Policy Statement 
2004, supra note 18. 
194
  See, e.g., HGSA Policy Statement 2004, supra note 18, at 3 (“Pilot studies should be undertaken 
to demonstrate the safety, effectiveness, validity and clinical utility of tests for additional disorders and new 
testing technologies.”). 
195
   I have used the term “universal pilot program” to refer to a pilot program testing the entire 
population of newborns within a state, thus making it universal.   
196
  See National Newborn Screening Report, supra note 191. 
197
  45 C.F.R. § 46.102(d) (1991). 
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research programs,198 and any research performed using federal funds,199 or 
otherwise subject to federal regulation, must comply with 45 C.F.R. § 46.200  
Section 46.117 of this regulation addresses the issue of informed consent and 
requires every research subject to give fully informed and voluntary consent 
to the procedure prior to testing.201  However, the regulations provide 
additional protections for research with children.202  If research poses only a 
minimal risk203 or offers direct benefit to the child, the consent of only one 
parent is required.204 Otherwise, the research requires the consent of both 
parents, unless the child has only one parent or legal guardian.205  Under 
either situation, the informed consent of at least one parent is required prior 
to testing.     
E. Allowing Parents to Consent on Behalf of Their Children for 
Expanded Newborn Screening Does Not Satisfy the Informed Consent 
Requirements of the United States 
The heightened requirements for research on children within the 
United States prevents parents from being required to consent before 
screening of disorders such as MCADD.  Despite the allowance for testing 
with parental consent under 45 C.F.R. § 46, the Maryland case of Grimes v. 
Kennedy Krieger Institute, Inc.206 provides a strong argument against 
allowing a requirement for such consent in the current situation.  This case 
held that parents cannot legally consent to the participation of their children 
in non-therapeutic research (research posing no potential benefit to the 
                                           
198
 See Angela R. Holder, Physician’s Failure to Obtain Informed Consent to Innovative Practice or 
Medical Research, 15 AM. JUR. PROOF OF FACTS 2d 711 § 3 (2005) (“After Nuremberg, and particularly in 
the early 1970’s, public outcry over obvious abuses of research subjects, some of whom did not even know 
that they were research subjects, led to several congressional investigations and consequent strict 
regulation, particularly as to the informed consent of the research subject in all federally-funded research 
activities, or those carried out in federal institutions.”). 
199
 Federal funds provide primary funding for newborn screening programs in the U.S., thus placing 
these programs under the provisions of 45 C.F.R. § 46 (1991). 
200
   45 C.F.R. § 46.101 (1991).  
201
  45 C.F.R. § 46.116 (1991) (general requirements for informed consent state that “[e]xcept as 
provided elsewhere in this policy, no investigator may involve a human being as a subject in research 
covered by this policy unless the investigator has obtained the legally effective informed consent of the 
subject or the subject’s legally authorized representative…”). 
202
  45 C.F.R. § 46, Subpart D (1991). 
203
  “’Minimal risk’ means that the probability and magnitude of harm or discomfort anticipated in the 
research are not greater in and of themselves than those ordinarily encountered in daily life or during the 
performance of routine physical or psychological examinations or tests.” 45 C.F.R. 46.102(i). 
204
  45 C.F.R. § 46.408(b). 
205
  Id. 
206
  782 A.2d 807 (Md. 2001).  
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child).207  The court stated that a parent “cannot consent to the participation 
of a child … in non-therapeutic research or studies in which there is any risk 
of injury or damage to the health of the subject.”208  In reaching this 
decision, the Grimes court relied upon a decision from the New York Court 
of Appeals.209  In T.D. v. New York Office of Mental Health,210 the Appellate 
Court determined that provisions in the regulations authorizing parents to 
consent on behalf of children for participation in non-therapeutic research 
posing greater than minimal risk to the child were insufficient.211  The 
Grimes court concurred with this conclusion in reaching its own holding.  
The decision in Grimes “sent shockwaves through the public health research 
community” due to its potential impact upon pediatric research.212  This 
impact clearly affects newborn screening, and state lawmakers should 
consider this legal precedent when deciding whether to utilize pilot 
programs in this area. 
Based upon the Grimes holding, treatment for each disorder proposed 
for addition into the newborn screening panel through pilot programs should 
first be required to offer a therapeutic benefit to the child.  Policy-makers 
should use a case-by-case analysis in making this determination.  If no 
therapeutic benefit is present, then testing may not involve a potential risk to 
the child as is required for incorporation of the disorder into screening. 
The pilot programs that states are using to study new disorders may be 
characterized as non-therapeutic research upon the child.  These programs 
provide no significant potential benefit to the child due to the rarity of the 
disorders and the lack of knowledge on the disorder itself.  Policy-makers 
cannot realistically view these disorders as providing a viable potential 
benefit to the child because they are incredibly rare.213  Furthermore, even if 
a child receives a positive result, MCADD has shown there may continue to 
be no benefit to that child because it is unknown whether they will ever 
become symptomatic.  Therefore, it is a stretch to say that a child is 
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   Id. at 857-858. 
208
  Id. at 858.  
209
  Id. at 858. 
210
  650 N.Y.S.2d 173 (N.Y. App. Div. 1996). 
211
 Id. at 191. 
212
 Anna C. Mastroianni & Jeffrey P. Kahn, Risk and Responsibility: Ethics, Grimes v. Kennedy 
Krieger, and Public Health Research Involving Children, 92 AM. J. PUB. HEALTH 1073, 1073 (2002); See 
also Efi Rubinstein, Going Beyond Parents and Institutional Review Boards in Protecting Children 
Involved in Nontherapeutic Research, 33 GOLDEN GATE U. L. REV. 251, 290 (2003) (suggesting that 
parents are not in the position to make decisions for their children due to potential conflicts of interests and 
recommending developing child advocacy programs for non-therapeutic research.) 
213
  For example, the average incidence rate for the 29 disorders recommended for screening by the 
March of Dimes is around 1 in 100,000.  For specific incidence rates, see March of Dimes, supra note 149. 
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receiving a benefit from the addition of these disorders onto the screening 
panel due to the odds of that particular child actually receiving any type of 
benefit. 
Under the Grimes ruling, since these programs offer no therapeutic 
benefit to the child, if they pose any risk to the child’s health the consent of 
the parent is insufficient.  The risk of discrimination, as well as potential 
physical and mental health problems resulting from the screening, are 
sufficient to negate the consent of the parent to this screening. 
The risks presented to the physical health of the newborn from 
receiving this screening range from minimal to life-threatening.  As was 
indicated through the hasty adoption of universal PKU screening, the 
treatment given to children with false positive test results can be severely 
debilitating, if not fatal.214  The presence of this risk alone is sufficient to 
conclude that this screening does not satisfy the Grimes standard.  
The potential negative impact of treatment, however, is not the only 
risk associated with such screening.  A positive test result can adversely 
affect the parent-child relationship by interrupting the first days of the 
newborn’s life when bonding is the most important.215  In this way, screening 
poses a risk to the mental health of the children involved. 
Another risk that arises is the potential for discrimination.216  In the 
early stages of any screening program, mislabeling will undoubtedly 
occur.217  Research has suggested that a positive test result can negatively 
affect the mental health of the child due to loss of self-esteem from being 
labeled as “diseased.”218  Children labeled as “diseased” forever carry the 
burden of such a designation, even if they never present symptoms.  This 
labeling can result in discrimination against the child, and perhaps even 
against the family.  In 1998, studies indicated that there had been 
approximately 200 documented cases of discrimination by insurance 
companies against healthy individuals based upon the presence of a genetic 
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  See Clayton, supra note 20, at 109.  
215
  See L.N. Al-Jader et al., Attitudes of Parents of Cystic Fibrosis Children Towards Neonatal 
Screening and Antenatal Diagnosis, 38 CLINICAL GENETICS 460, 460 n.114 (1990) (voicing concerns about 
the effect that a diagnosis has on the parent-child relationship). 
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   TED PETERS, GENETICS AND GENETHICS: ARE WE PLAYING GOD? (1997) (“Even with a 
government regulated program of access to basic health services, the need to purchase supplemental 
insurance to cover serious diseases makes many of us with certain genetic configurations vulnerable to 
discrimination.”). 
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  Id. at 105. 
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  The American Society of Human Genetics Board of Directors and The American College of 
Medical Genetics Board of Directors, Points to Consider: Ethical, Legal, and Psychosocial Implications of 
Genetic Testing in Children and Adolescents, 57 AM. J. HUMAN GENETICS 1233, 1238 (1995). 
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characteristic or trait revealed through genetic testing.219  Falsely labeled 
children are therefore at potential risk of never qualifying for adequate 
health insurance based upon a test given to them when they were just a few 
days old.  Families may also suffer a similar fate, as parents may be unable 
to obtain health insurance for their families based upon the knowledge of a 
genetic disorder within the family genome.220 
These potential risks, along with available legal precedent on parental 
consent to research, lead to the conclusion that policy-makers cannot easily 
solve the issues surrounding informed consent for the use of MS/MS in 
newborn screening.  Unlike Australia, simply requiring parents to provide 
such consent will not eliminate the potential legal problems implicated by 
such screening within the United States.  The issues surrounding informed 
consent should therefore serve to restrict the use of this technology to 
disorders fitting within the two criteria.  States should not include a disorder 
until it can fulfill these criteria, and screening of the child should not occur 
merely for the purpose of increasing knowledge of a particular disorder.  The 
fact that screening newborns is easier for the researchers due to the large 
pool of subjects available does not justify overstepping the rights of even a 
single child. 
F. Even If These Programs Are Classified As “Program Evaluation” 
Instead of Research, They Continue to Require Meaningful Consent 
from the Parents 
One final alternative for policy-makers is to justify MS/MS newborn 
screening as “program evaluation.”  The Center for Disease Control 
(“CDC”) has defined “program” to include any organized action such as a 
research project221 and “evaluation” as the systematic application of 
scientific methods to assess the design, implementation, improvement or 
outcomes of a program.222  These evaluations are conducted in order to 
discern whether programs should be “continued, improved, expanded, or 
curtailed [and] to assess the utility of new programs and initiatives.”223  The 
CDC temporarily excuses programs fitting within this definition from the 
requirements of 45 C.F.R. 46.  Despite qualifying as research, the use of 
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   Fruchtman & Pizzulli, supra note 178, at 413. 
220
  See Clayton, supra note 20, at 135. 
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  Center for Disease Control and Prevention, Framework for Program Evaluation in Public Health, 
48 MMWR 1, 311 (1999). 
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  See Peter H. Rossi & Howard E. Freeman, Evaluation: A Systematic Approach 5-9 (5th ed., 
1993). 
223
  Id. at 2. 
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MS/MS in newborn screening may be justified under this category.  If this is 
the case, policy-makers may find that the research is acceptable despite its 
failure to satisfy the legal precedent’s requirements for research upon 
children. 
Even if these programs are justified under the definition of “program 
evaluation,” there continues to be a need to at least require meaningful 
informed consent from the parent or guardian of the child screened.  While 
parental consent is not sufficient if the program is viewed as research,224 this 
specialized categorization of research does not justify returning to the “opt 
out” policy currently in use.225  Again, many of the disorders added to the 
screening panel do not fulfill the criteria for screening and therefore do not 
present a compelling rationale to deprive the fundamental rights of the 
parents.  Therefore, even if policy-makers categorize the use of MS/MS for 
newborn screening as “program evaluation,” they should at the least amend 
the informed consent policies to require more meaningful consent of the 
parents. 
VI. CONCLUSION 
Overall, while many states are already utilizing MS/MS to screen for 
up to thirty-two inborn errors of metabolism,226 this analysis indicates that 
more caution is necessary in the future before continuing down this path.  
The capability of the technology should not outweigh reason when 
incorporating new disorders into screening programs.  While the adoption of 
MS/MS into the Australian newborn screening programs was successful, 
differences in the informed consent of the United States requirements 
prevent it from following an identical path.  State policy-makers must 
address informed consent and should amend the current policy to require 
more meaningful consent from the parent or guardian.  These policy-makers 
should also consider how to address the criteria designed to give guidance 
when incorporating new disorders into the screening panel.  If they choose to 
continue to rely upon these criteria, these policy-makers should use care not 
to expand screening for disorders failing to fulfill these criteria.  Both of 
these recommendations will require caution by the states.  Only by using 
caution can the United States avoid the problems experienced in the early 
days of PKU screening.  Policy-makers should therefore use care to ensure 
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  See supra Section V(D)(i). 
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  See supra Section V(C). 
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  North Dakota mandates screening all newborns for 32 disorders through MS/MS technology. 
NATIONAL NEWBORN SCREENING STATUS REPORT, supra note 101. 
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that the disorders included within their states’ screening panel are 
sufficiently understood to prevent a similar result.  The rights of the newborn 
child must remain at the forefront throughout all of these discussions.  Such 
consideration will limit screening to situations where the test is beneficial to 
the child.  In this way, technology can exist harmoniously with the deeply-
rooted principles of the American legal system. 
